Evogene (EVGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.70M
Last updated: Nov 17, 2026 at 11:05 AM ET
Evogene (EVGN) Earnings: Report Dates and Results
Evogene (EVGN) is confirmed to report earnings on Nov 19, 2026, before the open. In the quarter ended Jun 30, 2026, Evogene reported EPS of -$0.13, above the -$0.27 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EVGN has a confirmed report date of Nov 19, 2026, before the open.
EVGN Earnings Call
The latest EVGN earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 38 quarters below that had an estimate, EVGN beat 15, missed 21 and matched 2. Revenue for the quarter ended Jun 30, 2026 was $347000, down 60.7% from $884000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.13 | -$0.27 | -$0.27 - -$0.27 | +51.85% | Beat | N/A | 1 | 1 up, 0 down | Aug 18, 2026 | $347000 |
| Mar 31, 2026 | -$0.61 | -$0.27 | -$0.27 - -$0.27 | -125.93% | Miss | N/A | 1 | 0 up, 0 down | May 20, 2026 | $334000 |
| Dec 31, 2025 | -$0.62 | -$0.41 | N/A | -50.59% | Miss | -1129.0% | 1 | 1 up, 1 down | Mar 5, 2026 | $314000 |
| Sep 30, 2025 | -$0.46 | -$0.41 | -$0.41 - -$0.41 | -12.20% | Miss | N/A | 1 | 2 up, 0 down | Nov 20, 2025 | $312000 |
| Jun 30, 2025 | -$0.50 | -$0.63 | -$0.65 - -$0.61 | +20.63% | Beat | N/A | 2 | 1 up, 1 down | Aug 28, 2025 | $884000 |
| Mar 31, 2025 | -$0.38 | -$0.50 | -$0.53 - -$0.48 | +24.00% | Beat | N/A | 2 | 1 up, 0 down | May 21, 2025 | $2.44M |
| Dec 31, 2024 | $0.06 | -$0.73 | -$0.76 - -$0.69 | +108.28% | Beat | N/A | 2 | 1 up, 1 down | Mar 6, 2025 | $1.61M |
| Sep 30, 2024 | -$1.31 | -$1.01 | -$1.17 - -$0.85 | -29.70% | Miss | N/A | 2 | 1 up, 1 down | Nov 21, 2024 | $1.74M |
| Jun 30, 2024 | -$1.06 | -$1.20 | -$1.30 - -$1.20 | +11.67% | Beat | N/A | 2 | 0 up, 0 down | Aug 22, 2024 | $605000 |
| Mar 31, 2024 | -$0.80 | -$0.90 | -$1.00 - -$0.80 | +11.11% | Beat | N/A | 2 | 1 up, 0 down | May 23, 2024 | $4.19M |
| Dec 31, 2023 | -$1.30 | -$1.40 | -$1.40 - -$1.40 | +7.14% | Beat | N/A | 2 | 0 up, 0 down | Mar 7, 2024 | $578000 |
| Sep 30, 2023 | -$0.80 | -$1.57 | -$1.70 - -$1.40 | +49.04% | Beat | N/A | 3 | 0 up, 0 down | Nov 15, 2023 | $3.77M |
| Jun 30, 2023 | -$1.70 | -$1.75 | -$1.90 - -$1.60 | +2.86% | Beat | N/A | 2 | 0 up, 0 down | Aug 17, 2023 | $654000 |
| Mar 31, 2023 | -$1.50 | -$1.60 | -$1.60 - -$1.60 | +6.25% | Beat | N/A | 1 | 0 up, 0 down | May 18, 2023 | $641000 |
| Dec 31, 2022 | -$0.07 | -$0.20 | -$0.21 - -$0.19 | +65.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 9, 2023 | $641000 |
| Sep 30, 2022 | -$1.60 | -$1.97 | N/A | +18.78% | Beat | N/A | 1 | 0 up, 0 down | Nov 17, 2022 | $466000 |
| Jun 30, 2022 | -$2.10 | -$1.90 | N/A | -10.53% | Miss | N/A | N/A | N/A | Aug 31, 2022 | $312000 |
| Mar 31, 2022 | -$2.00 | -$1.80 | N/A | -11.11% | Miss | N/A | N/A | N/A | May 26, 2022 | $237000 |
| Dec 31, 2021 | -$1.80 | -$2.00 | -$2.00 - -$1.50 | +10.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 10, 2022 | $311000 |
| Sep 30, 2021 | -$1.90 | -$1.77 | -$1.90 - -$1.50 | -7.34% | Miss | N/A | 2 | 0 up, 0 down | Nov 17, 2021 | $151000 |
| Jun 30, 2021 | -$1.50 | -$1.65 | N/A | +9.09% | Beat | N/A | N/A | N/A | Aug 11, 2021 | $135000 |
| Mar 31, 2021 | -$1.70 | -$1.80 | N/A | +5.56% | Beat | N/A | N/A | N/A | May 26, 2021 | $333000 |
| Dec 31, 2020 | -$2.50 | -$1.70 | N/A | -47.06% | Miss | N/A | N/A | N/A | Mar 3, 2021 | $351000 |
| Sep 30, 2020 | -$0.17 | -$0.17 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 18, 2020 | $316000 |
| Jun 30, 2020 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 5, 2020 | $298000 |
| Mar 31, 2020 | -$0.24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 26, 2020 | $75000 |
| Dec 31, 2019 | -$0.24 | $0.34 | N/A | -170.59% | Miss | N/A | N/A | N/A | Mar 4, 2020 | $116000 |
| Sep 30, 2019 | -$0.16 | $0.18 | N/A | -188.89% | Miss | N/A | N/A | N/A | Nov 13, 2019 | $97000 |
| Jun 30, 2019 | -$0.16 | $0.19 | N/A | -184.21% | Miss | N/A | N/A | N/A | Jul 31, 2019 | $192000 |
| Mar 31, 2019 | -$0.15 | $0.30 | N/A | -150.00% | Miss | N/A | N/A | N/A | May 28, 2019 | $348000 |
| Dec 31, 2018 | -$0.23 | -$0.19 | N/A | -21.05% | Miss | N/A | N/A | N/A | Mar 13, 2019 | $635000 |
| Sep 30, 2018 | -$1.90 | -$1.80 | N/A | -5.56% | Miss | N/A | N/A | N/A | Nov 14, 2018 | $367000 |
| Jun 30, 2018 | -$1.90 | -$1.90 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 8, 2018 | $379000 |
| Mar 31, 2018 | -$2.10 | -$1.90 | N/A | -10.53% | Miss | N/A | N/A | N/A | May 29, 2018 | $366000 |
| Dec 31, 2017 | -$2.40 | -$2.10 | -$2.10 - -$2.10 | -14.29% | Miss | N/A | 1 | N/A | Feb 28, 2018 | $734000 |
| Sep 30, 2017 | -$2.00 | -$1.70 | N/A | -17.65% | Miss | N/A | N/A | N/A | Nov 22, 2017 | $748000 |
| Jun 30, 2017 | -$1.80 | -$1.40 | N/A | -28.57% | Miss | N/A | N/A | N/A | Aug 10, 2017 | $1.18M |
| Mar 31, 2017 | -$1.90 | -$1.80 | N/A | -5.56% | Miss | N/A | N/A | N/A | May 17, 2017 | $721000 |
| Dec 31, 2016 | -$2.60 | -$1.80 | N/A | -44.44% | Miss | N/A | N/A | N/A | Feb 27, 2017 | $1.18M |
| Sep 30, 2016 | -$2.00 | -$0.70 | N/A | -185.71% | Miss | N/A | N/A | N/A | Nov 21, 2016 | $1.54M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.96, after -$3.11 the year before. It was -$7.70 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.96 | N/A |
| Dec 31, 2024 | -$3.11 | N/A |
| Dec 31, 2023 | -$5.30 | N/A |
| Dec 31, 2022 | -$5.77 | N/A |
| Dec 31, 2021 | -$6.90 | N/A |
| Dec 31, 2020 | -$3.07 | N/A |
| Dec 31, 2019 | -$0.71 | N/A |
| Dec 31, 2018 | -$6.13 | N/A |
| Dec 31, 2017 | -$8.10 | N/A |
| Dec 31, 2016 | -$7.70 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 6,200 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 6,199 | 5 | |
| 2026Q1 | Mar 31, 2026 | 4,483 | 6 | |
| 2025Q4 | Dec 31, 2025 | 3,876 | 3 | |
| 2025Q3 | Sep 30, 2025 | 5,918 | 3 | |
| 2025Q2 | Jun 30, 2025 | 4,610 | 3 | |
| 2025Q1 | Mar 31, 2025 | 5,818 | 3 | |
| 2024Q4 | Dec 31, 2024 | 6,366 | 4 | |
| 2024Q3 | Sep 30, 2024 | 5,564 | 4 |
2026Q2 Earnings Call
Opening remarks
Ofer Haviv CEO Thank you for joining Evogene's Second Quarter 2026 Analyst Call. Today's call will be somewhat different from our usual format. Joining me is Mr. Nir Nimrodi, Chairman of Evogene's Board of Directors. Nir will begin by presenting the Board's response to the recent demand by a group of dissident shareholders seeking to replace the company's Board. Following Nir's remarks, I will discuss the company's achievements during the first half of the year and our near-term expectations. We will conclude with a review by Mrs. Polina Ravzin, Evogene's VP Finance, of our financial results, followed by a Q&A session. Nir, please go ahead.
Nir Nimrodi Chairman Thank you, Ofer. Good morning, everyone. As Chairman, my primary responsibility together with my fellow directors is to position Evogene for long-term sustainable value creation. We share the frustration with the historical share price, and we acted with urgency and determination to address it. Over the past 18 months, we haven't just talked about change, we have delivered it. We have fundamentally transformed Evogene into a lean, AI-driven leader in computational chemistry for pharmaceuticals and crop protection. We have streamlined operations, reduced costs and optimized our portfolio. The question today is not whether change is necessary — change has already been executed. The question is how we accelerate the momentum we have created. Interrupting this transformation precisely as it enters its most promising phase is a risk we cannot afford. Our strategy is already delivering tangible results. We established ChemPass as our core platform, building the first-in-class generative small molecule foundation model and integrating autonomous AI agents in partnership with Google Cloud. We secured six key drug development agreements with leading biotechnology companies and premier academic institutions, validating the commercial value of our AI-driven platform, ChemPass AI. We reduced headcount from 117 to 38, creating a highly focused, agile organization. We lowered cash burn from approximately $20.5 million in 2024 to an expected $8.5 million to $9.5 million in 2026 with further reductions anticipated in 2027. We raised approximately $11.1 million in new capital, securing the financial runway to execute our plans. And lastly, we monetized Lavie Bio, selling it to ICL for $15.25 million, licensed Biomica's Phase I asset to Lishan Biotech, focused Casterra on the Brazil SAF market and advanced AgPlenus novel fungicide discovery. Another strong indication of confidence in Evogene's long-term potential comes from Mr. Leon Recanati, a member of Evogene's Board of Directors and a highly respected investor. Mr. Recanati recently made a significant investment in Evogene and today he is one of the largest shareholders of the company. This recent investment reflects his strong belief in Evogene's strategy, technology and long-term value creation potential.
Frequently Asked Questions About EVGN
When is Evogene's next earnings date?
Evogene's next earnings report is confirmed for Nov 19, 2026, before the open.
Did EVGN beat earnings estimates last quarter?
Yes. Evogene reported EPS of -$0.13 for the quarter ended Jun 30, 2026, above the -$0.27 estimate, a 51.85% surprise.
What EPS do analysts expect from EVGN next quarter?
The consensus EPS estimate for Evogene for the quarter ended Sep 30, 2026 is -$0.19 from 1 analyst, with estimates from -$0.19 to -$0.19.
How often does EVGN beat earnings estimates?
Evogene beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.71%.
Does EVGN report before or after the market opens?
Evogene is confirmed to report on Nov 19, 2026, before the market opens.
EVGN pages: Overview, Earnings, Forecast, Financials, Competitors